Market Overview

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
Related MYL
The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen
The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
FDA Commish touts advances/successes (Seeking Alpha)

Biotech stocks are at the mercy of market-moving catalysts, and Cantor Fitzgerald analyst Louise Chen outlined potential outlined potential stock-moving events for eight biotech names in a Monday report. 

Mylan: Pipeline Update, Patent Challenge

Mylan N.V. (NASDAQ: MYL) is scheduled to hold its investor day in New York City on April 11. The company is expected to shed light on the following: 

  • A recently announced biosimilar Botox program with Revance Therapeutics Inc (NASDAQ: RVNC).
  • A Humira biosimilar program.
  • Its platform and pipeline.

A U.S. Patent Trial and Appeal Board oral hearing for Allergan plc Ordinary Shares (NYSE: AGN)'s Restasis is scheduled for April 3. The PTAB denied St. Regis Mohawk Tribe's motion to terminate Mylan's Restasis challenge over six Restasis-related patents, according to a Feb. 26 release from Mylan.

A final decision on the challenged patents is scheduled for June 6.

Horizon: Enrolling For RECIPE, TRIPLE Trials

Horizon Pharma PLC (NASDAQ: HZNP) plans to begin enrolling patients in the RECIPE trial for krystexxa. Krystexxa is the first and only biologic for uncontrolled gout — the most common form of inflammatory arthritis — that rapidly reverses disease progression, according to a company presentation. Horizon expects krystexxa net sales growth of over 50 percent in 2018.

The biotech firm plans to start the immunomodulation arm of its TRIPLE study in the first quarter. 

Positive Trial Results Expected For Heron's Postoperative Pain Med

Cantor Fitzgerald expects Heron Therapeutics Inc (NASDAQ: HRTX) to announce positive Phase 3 trial results for HTX-011 as early as April. HTX-011 combines the local anesthetic bupivacaine in a fixed dose with anti-inflammatory meloxicam for postoperative pain. 

See also: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Midstage Trial Results For Cidara's Antifungal 

Cidara Therapeutics Inc (NASDAQ: CDTX) is expected to release positive results for its Phase 2 study of CD101 IV/Rezafungin for systemic infections early in the week of March 19, according to Cantor Fitzgerald. 

Watch For Positive Neos News 

Neos Therapeutics Inc (NASDAQ: NEOS) is scheduled to host its investor day March 22, which Cantor Fitzgerald projects will be incrementally positive for the company's stock.

Twin Catalysts For Revance

Revance is due to complete its Phase 2a trial for its RT002 for the treatment of plantar fasciitis in the first quarter of 2018. Although interim results from the study did not meet the primary endpoint, Revance plans to review full data from the study and conduct another Phase 2a trial with a modified design, analyst Chen said.

Revance hosts its analyst day April 19.

Evolus Presents At Two Conferences 

Evolus Inc (NASDAQ: EOLS) is due to present data from its EVB-003 study for botulinum toxin DWP-450 at the Australasian Society of Aesthetic Plastic Surgery and the Aesthetic & Anti-Aging Medicine World Congress meetings in April. 

Paratek Awaits FDA Acceptance 

Chen said she expects FDA acceptance for Paratek Pharmaceuticals Inc (NASDAQ: PRTK)'s NDA filing for omadacycline, indicated for acute bacterial infections, in early April, with approval likely to come in early October. The NDA was filed in early February. 

Related Link:

7 Biotech Stocks With Clinical Trial Outcomes In March

Latest Ratings for MYL

Nov 2018ArgusUpgradesHoldBuy
Nov 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Nov 2018RBC CapitalMaintainsOutperformOutperform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Previews FDA Top Stories Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (AGN + CDTX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

KeyBanc Says SaaS Investors Should Remain Bullish, But Selective

Where AI, Data, Blockchain Fit In The Trucking Industry